Last $34.89 USD
Change Today +3.08 / 9.68%
Volume 74.5K
SAGE On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
OTC US
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SAGE) Snapshot

Open
$31.58
Previous Close
$31.81
Day High
$35.51
Day Low
$30.52
52 Week High
10/6/14 - $40.74
52 Week Low
07/29/14 - $24.25
Market Cap
897.1M
Average Volume 10 Days
68.8K
EPS TTM
--
Shares Outstanding
25.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SAGE)

Related News

No related news articles were found.

sage therapeutics inc (SAGE) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SAGE) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

25 Employees
Last Reported Date: 08/14/14
Founded in 2011

sage therapeutics inc (SAGE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $153.0K
Chief Medical Officer
Total Annual Compensation: $149.0K
Chief Scientific Officer
Total Annual Compensation: $302.5K
Compensation as of Fiscal Year 2013.

sage therapeutics inc (SAGE) Key Developments

Sage Therapeutics, Inc.(NasdaqGM:SAGE) added to Russell 2000 Index

Sage Therapeutics, Inc. will be added to the Russell 2000 Index.

Sage Therapeutics, Inc.(NasdaqGM:SAGE) added to Russell 3000 Index

Sage Therapeutics, Inc. will be added to the Russell 3000 Index.

Sage Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 10:40 AM

Sage Therapeutics, Inc. Presents at Leerink Rare Disease Roundtable, Oct-01-2014 10:40 AM. Venue: Le Parker Meridian Hotel, New York, New York, United States. Speakers: Jeffrey M. Jonas, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAGE:US $34.89 USD +3.08

SAGE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SAGE.
View Industry Companies
 

Industry Analysis

SAGE

Industry Average

Valuation SAGE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.